NIPH Clinical Trials Search

Extension Study for Participants in Studies That Include Belzutifan

Basic Information

Recruitment status	Pending
Health condition(s) or Problem(s) studied	advanced solid tumors or von Hippel-Lindau-related neoplasms
Date of first enrollment	12/06/2026
Target sample size	4
Countries of recruitment	USA,Japan,Canada,Japan,Brazil,Japan,Chile,Japan,Colombia,Japan,Belgium,Japan,Czech Republic,Japan,Denmark,Japan,Finland,Japan,France,Japan,Germany,Japan,Hungary,Japan,Israel,Japan,Netherlands,Japan,Poland,Japan,Russia,Japan,Spain,Japan,United Kingdom,Japan,Ukraine,Japan,Australia,Japan,New Zealand,Japan,South Korea,Japan,Taiwan,Japan
Study type	Interventional
Intervention(s)	Belzutifan 120 mg, oral, once daily (QD) until progressive disease or discontinuation

Outcome(s)

Primary Outcome	Overall Survival (OS) :The time from randomization or the first dose of any study intervention in the parent study to death due to any cause
Secondary Outcome	- AEs - Discontinuation of study intervention due to AEs

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	- Participants with advanced solid tumors or von Hippel-Lindau-related neoplasms who are participating in belzutifan-containing studies and on active treatment in a belzutifan parent study.
Exclude criteria	- Has an on-going serious adverse event in the parent study, unless no longer hospitalized and considered clinically stable. - Is currently on a dose interruption due to an Adverse Event (AE) in the parent study; once treatment has been resumed in the parent study, the participant is eligible to enroll.